Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637006 | 0.86 | GRM5 (0.48) | GRM5CYP3A4HRH4CYP1A2 | |
| SCHEMBL3645605 | 0.86 | GRM5 (0.49) | GRM5CYP3A4HRH4CYP1A2 | |
| SCHEMBL3636727 | 0.85 | GRM5 (0.53) | GRM5CYP3A4HRH4CYP1A2 | |
| SCHEMBL3638411 | 0.85 | GRM5 (0.54) | GRM5CYP3A4HRH4CYP1A2 | |
| SCHEMBL3639435 | 0.82 | GRM5 (0.49) | GRM5CYP3A4HRH4CYP1A2 | |
| SCHEMBL3645939 | 0.82 | GRM5 (0.63) | GRM5CYP3A4 | |
| SCHEMBL3643031 | 0.81 | GRM5 (0.50) | GRM5CYP3A4HRH4 | |
| SCHEMBL3639672 | 0.81 | GRM5 (0.54) | GRM5CYP3A4HRH4CYP1A2 | |
| SCHEMBL3642547 | 0.80 | GRM5 (0.58) | GRM5CYP3A4CYP1A2 | |
| SCHEMBL3643043 | 0.79 | GRM5 (0.59) | GRM5CYP3A4HRH4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | claimed |
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | claimed |
| EP-2178858-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2010-04-28 | — | — | EP | claimed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | claimed |
| WO-2009015897-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-05 | — | — | WO | claimed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2178858-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2010-04-28 | — | — | EP | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009015897-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | GRM5 1/4885CYP3A4 2602/4885HRH4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.